The regulatory drama playing out between the FDA and biotech firms just took its sharpest turn yet. On June 17, 2026, UniQure announced that the US Food and Drug Administration completely reversed its stance on the company's experimental gene therapy for Huntington’s disease, AMT-130. The federal agency agreed that UniQure can file for accelerated approval using existing three-year data from its Phase 1/2 study. This completely bypasses a previous demand for an immediate, massive Phase 3 trial.
This unexpected about-face sent UniQure’s stock skyrocketing over 74% in a single day. For the 30,000 to 41,000 Americans living with Huntington’s disease, it represents something far more critical: a sudden acceleration toward the first-ever treatment designed to slow down this fatal, mind-robbing condition.
The Regulatory Whiplash Behind AMT-130
To understand how big this shift is, you have to look at the chaotic timeline that preceded it. Huntington’s disease is a genetic death sentence. It systematically destroys nerve cells in the brain, stripping away a person's motor skills, cognitive faculties, and mental health over years of agonizing decline. Right now, every single approved drug only treats the symptoms, like chorea (involuntary twitching). Nothing stops the actual destruction of the brain.
UniQure designed AMT-130 to fix that. Delivered via a one-time brain surgery, the therapy uses a harmless viral vector to pump engineered micro-RNA directly into the striatum. The goal is to silence the mutated HTT gene, blocking the production of the toxic huntingtin protein that kills brain cells.
Last year, the data looked stellar. In September 2025, UniQure reported that patients on the higher dose saw a whopping 75% slowing of disease progression at the three-year mark compared to historical control data. The company prepared for a quick regulatory filing.
Then the bureaucratic hammer dropped.
By November 2025, a newly aggressive FDA leadership team, spearheaded by Commissioner Marty Makary and Vinay Prasad, pulled the rug out. They declared the early-stage data insufficient, heavily criticizing the use of external historical controls. In March 2026, the agency officially demanded a full randomized trial. Worse, they insisted on a sham surgery control group. That meant surgeons would literally have to drill holes into the skulls of a control group of Huntington's patients without delivering the actual medicine.
Predictably, the biotech world revolted. Analysts called it a worst-case scenario, and patient advocates called the sham surgery requirement highly unethical. The friction became deeply personal when an anonymous FDA official panned the drug to reporters, sparking a public feud that eventually led to Prasad leaving the agency in April 2026.
Now, just two months after that internal explosive fallout, the FDA has folded.
Inside the New Accelerated Approval Strategy
With Prasad gone and the agency operating in a more flexible mode, the FDA's fresh Type B meeting minutes show a path forward that aligns closely with what UniQure originally wanted.
Instead of waiting years to enroll and run a massive Phase 3 study before anyone can get the drug, UniQure will submit its Biologics License Application (BLA) for accelerated approval in the third quarter of 2026. The existing three-year data from just 26 American patients will serve as the primary evidence.
The compromise hinges on a post-marketing confirmatory study. The FDA still wants UniQure to run a trial to confirm the drug actually works in the real world, but the parameters have dramatically changed:
- No more mandatory sham surgeries: The FDA is currently negotiating a confirmatory trial design that can utilize a standard-of-care control group instead of a placebo surgery.
- Concurrent tracking: Patients can potentially access the drug commercially while the safety and efficacy verification trial runs simultaneously.
- Fast conditional rollout: If approved under this pathway, AMT-130 could hit the market as early as 2027.
The stakes here are incredibly high. If the confirmatory study later shows that the 75% slowing of progression was a statistical fluke and the drug doesn't work, the FDA will pull AMT-130 from shelves immediately. But for an entirely fatal disease with zero alternatives, it’s a gamble patients and doctors are eager to take.
What This Means for Patients and the Biotech Market
If you look past the immediate corporate wins, this regulatory pivot signals a much broader shift in how the US government treats advanced genetic therapies for rare diseases.
For years, the FDA treated gene therapies like traditional small-molecule pills, demanding massive patient enrollment pools. But rare diseases don't have massive patient pools. Recruiting hundreds of people with early manifest Huntington's disease to undergo experimental brain surgery is incredibly difficult. Requiring them to sign up for a fake brain surgery is practically impossible.
By accepting early-stage data compared against high-quality natural history datasets, the FDA is opening the door for other stalled genetic pipelines. Look at companies like Capricor Therapeutics, Disc Medicine, or Biohaven. They have all hit similar regulatory brick walls recently, only to find the FDA suddenly showing renewed flexibility in mid-2026.
What Happens Next
If you are tracking this space as an investor, clinician, or patient family member, don't break out the champagne just yet. A green light to file is not a guarantee of approval.
Your next step is to watch for the official filing in Q3 2026. Around that same time, UniQure expects to release its four-year durability data for AMT-130. While this four-year data won't be the primary basis of the FDA filing, it will act as a major indicator of whether the gene-silencing effect is truly permanent or if it fades over time.
Keep a close eye on the final design layout of the confirmatory trial. The exact wording of the upcoming FDA agreement will dictate how easily UniQure can recruit patients for that study. If the agency completely drops the sham surgery requirement in writing, expect the stock to surge again and the trial to fill up in record time.
